BR0317586A - Compostos para normalização do ciclo sono/vigìlia - Google Patents

Compostos para normalização do ciclo sono/vigìlia

Info

Publication number
BR0317586A
BR0317586A BR0317586-3A BR0317586A BR0317586A BR 0317586 A BR0317586 A BR 0317586A BR 0317586 A BR0317586 A BR 0317586A BR 0317586 A BR0317586 A BR 0317586A
Authority
BR
Brazil
Prior art keywords
sleep
containing compound
compound
compounds
adenosine
Prior art date
Application number
BR0317586-3A
Other languages
English (en)
Inventor
Perry F Renshaw
Scott Lukas
Original Assignee
Mclean Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mclean Hospital Corp filed Critical Mclean Hospital Corp
Publication of BR0317586A publication Critical patent/BR0317586A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTOS PARA NORMALIZAçãO DO CICLO SONO/VIGìLIA". A invenção provê métodos para normalização do ciclo sono/vigília de um mamífero por administração ao mamífero de um montante terapeuticamente eficaz de um composto contendo citidina, composto contendo citisina, composto contendo uridina, composto contendo creatina, composto contendo adenosina, ou composto de elevação de adenosina. Assim, os métodos descritos aqui podem aumentar o estado desperto, reduzir o cansaço ou fadiga durante o dia, e melhorar a qualidade sono. Os métodos da invenção podem também ser usados no tratamento de distúrbios do sono, como insónia, apnéia do sono, movimentos periódicos dos membros, síndrome das pernas inquietas, narcolepsia, e sonolência problemática, ou para aumentar a função cognitiva em indivíduos privados do sono. Citicolina é um exemplo de composto para uso nos métodos aqui descritos.
BR0317586-3A 2002-12-20 2003-12-17 Compostos para normalização do ciclo sono/vigìlia BR0317586A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43545702P 2002-12-20 2002-12-20
PCT/US2003/040450 WO2004058160A2 (en) 2002-12-20 2003-12-17 Compounds for the normalization of the sleep/wake cycle

Publications (1)

Publication Number Publication Date
BR0317586A true BR0317586A (pt) 2005-11-22

Family

ID=32682243

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317586-3A BR0317586A (pt) 2002-12-20 2003-12-17 Compostos para normalização do ciclo sono/vigìlia

Country Status (12)

Country Link
US (1) US20040176316A1 (pt)
EP (1) EP1589979A4 (pt)
JP (2) JP4717444B2 (pt)
CN (1) CN100563660C (pt)
AU (1) AU2003299715A1 (pt)
BR (1) BR0317586A (pt)
CA (1) CA2508995A1 (pt)
MX (1) MXPA05006781A (pt)
NO (1) NO20052987L (pt)
RU (1) RU2366428C2 (pt)
UA (1) UA88869C2 (pt)
WO (1) WO2004058160A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
CN100430066C (zh) * 2002-11-08 2008-11-05 麦克莱恩医院 用于烟草依赖性和戒断治疗的化合物
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
JP2007508315A (ja) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法
EP1765364A4 (en) * 2004-06-10 2010-09-22 Mclean Hospital Corp PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1784199A4 (en) * 2004-08-11 2010-06-23 Mclean Hospital Corp COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION
JP5566603B2 (ja) * 2005-05-23 2014-08-06 マサチューセッツ インスティテュート オブ テクノロジー Ｐｕｆａを含有する組成物及びそれを使用した方法
TW200827367A (en) * 2006-10-26 2008-07-01 Kyowa Hakko Kogyo Kk A therapeutic agent for irritable bowel syndrome
WO2009065119A2 (en) * 2007-11-16 2009-05-22 Bio Clinical Development, Inc. Edible energy composition with low caffeine
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
JP5426918B2 (ja) * 2009-04-20 2014-02-26 株式会社 伊藤園 ウリジンを含有する抗疲労剤又は体力向上剤
JP2011032232A (ja) * 2009-08-04 2011-02-17 Ito En Ltd 興奮抑制用又は鎮静用組成物及びこれを含む飲食品
JP5989319B2 (ja) 2011-10-06 2016-09-07 ライオン株式会社 睡眠の質改善剤
MX2014014813A (es) * 2012-06-04 2015-02-12 Pfizer Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño.
CN105101974B (zh) * 2013-04-05 2018-07-03 狮王株式会社 内服组合物
EP3056096B1 (de) * 2015-02-05 2019-07-24 Smart Sleep GmbH Verwendung eines Nahrungsergänzungsmittels enthaltend Kreatin zur Reduktion des natürlichen Schlafbedarfs oder zur schnelleren Anpassung der zirkadianen Rhythmik an neue Zeitzonen
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048316A (en) * 1974-03-04 1977-09-13 Penn Nathar W Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning
US4115576A (en) * 1974-04-02 1978-09-19 Penn Nathar W Compositions and method of employing the same for inhibiting alcohol intoxication
US4027017A (en) * 1974-07-16 1977-05-31 Chugai Seiyaku Kabushiki Kaisha Method of treating alcoholism
IT1200589B (it) * 1985-02-14 1989-01-27 Gibipharma Spa Derivati naturali attivita farmagologica
JPS63208524A (ja) * 1987-02-25 1988-08-30 Nippon Oil & Fats Co Ltd 睡眠リズム改善剤
US5691320A (en) * 1987-10-28 1997-11-25 Pro-Neuron, Inc. Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
US5635486A (en) * 1990-05-11 1997-06-03 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Ophthalmic composition comprising a sleep adjusting substance
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
ES2153360T3 (es) * 1991-05-29 2001-03-01 Abbott Lab Compuestos de isoxazol e de isotiazol que mejoran las funciones de razonamiento.
US5704361A (en) * 1991-11-08 1998-01-06 Mayo Foundation For Medical Education And Research Volumetric image ultrasound transducer underfluid catheter system
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
US5472958A (en) * 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
WO1998006855A1 (en) * 1996-08-16 1998-02-19 The Texas A & M University System Compositions and methods for delivery of nucleic acids to hepatocytes
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
WO2000006174A1 (en) * 1998-07-31 2000-02-10 Massachusetts Institute Of Technology Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases
DE19929995B4 (de) * 1999-06-30 2004-06-03 Skw Trostberg Ag Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
ES2170649B1 (es) * 2000-03-29 2003-06-16 Ferrer Int Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline

Also Published As

Publication number Publication date
JP2006513214A (ja) 2006-04-20
JP2011102319A (ja) 2011-05-26
CN1750833A (zh) 2006-03-22
WO2004058160A3 (en) 2005-03-31
NO20052987L (no) 2005-08-29
EP1589979A4 (en) 2009-04-01
CN100563660C (zh) 2009-12-02
US20040176316A1 (en) 2004-09-09
MXPA05006781A (es) 2005-09-30
JP4717444B2 (ja) 2011-07-06
RU2366428C2 (ru) 2009-09-10
RU2005122934A (ru) 2006-01-20
UA88869C2 (ru) 2009-12-10
AU2003299715A1 (en) 2004-07-22
WO2004058160A2 (en) 2004-07-15
NO20052987D0 (no) 2005-06-17
CA2508995A1 (en) 2004-07-15
AU2003299715A8 (en) 2004-07-22
EP1589979A2 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
BR0317586A (pt) Compostos para normalização do ciclo sono/vigìlia
CY1109079T1 (el) Συνθεσεις που περιλαμβανουν μονταφινιλη για την θεραπεια διαταραχης ελλειψης προσοχης υπερδραστικοτητας
ES2165878T3 (es) Utilizacion del modafinil para el tratamiento de las apneas del sueño y trastornos de ventilacion de origen central.
CY1105729T1 (el) Παραγοντες με σχετιζομενη με σεροτονινη δραση για την αντιμετωπιση για υπνικη απνοια
IT1306681B1 (it) Struttura di capo traspirante da indossare per migliorare il comfortdel corpo umano.
BR0315846A (pt) Tratamento farmacológico para apnéia do sono
MEP35308A (en) COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF
PT1261333E (pt) Utilizacao de topiramato para o tratamento e diagnostico de transtorno do sono relacionado com a respiracao e meios para realizar o metodo e o diagnostico
HUP0101645A2 (hu) Riluzol és L-DOPA kombinációi a Parkinson kór kezelésére
BR0307041A (pt) Corpos de fosfolipìdio e uso dos mesmos no tratamento de doenças inflamatórias e autoimunes
ATE421313T1 (de) Verwendung einer dihydrochalcon-reichen phenolischen fraktion für eine kosmetische behandlung
PT1030667E (pt) Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
NO20005757D0 (no) Cabergolin og pramipexol - nye anvendelser og kombinasjoner
DE602004025683D1 (de) Therapeutische zubereitung für autoimmune erkrankungen
Zellini et al. Video-polysomnographic aspects of painful legs and moving toes syndrome
CN208823097U (zh) 一种固定效果好的骨科固定装置
Knuckles et al. Yellow nail syndrome in association with sleep apnea.
CN2368482Y (zh) 防止打鼾器
WO2008077127A3 (en) Use of modafinil to treat restless leg syndrome
Evans et al. Is it migraine or cluster?
MX2021016090A (es) Lemborexant para el tratamiento de problemas del sueño.
ITPD980294A1 (it) Struttura di capo traspirante da indossare per migliorare il comfort del corpo umano.
BR0314945A (pt) Uso de antagonistas de receptor 5-ht2 para tratamento de distúrbios de sono
KR940000088A (ko) 지압용 고무장갑
MX9503363A (es) N-(2,6-dioxo-3-piperidil) ftalimida (generico talidomida como tratamiento del sindrome de desgaste asociado con la infeccion por vih-1.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.